Developer docs
API playgroundTry for free, no card

Search company profiles

Reliant AI

Full company profile

uuid0000r9d

Namestring
Reliant AI
Legal namestring
Reliant AI, Inc.
Websiteurl
reliant.ai
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Reliant AI was a Canadian applied-AI company that built domain-specific generative AI tooling for the biopharma industry. Its flagship product, Reliant Tabular, was an AI workbench that automated systematic literature reviews, competitive landscaping, evidence synthesis, and clinical trial analytics for pharmaceutical and biotechnology companies and the consulting firms that serve them. The platform combined proprietary fine-tuned large language models (including a fine-tuned version of Llama 3.1 70B), reinforcement learning, retrieval-augmented generation, and "densified knowledge graphs" covering 38M+ scientific publications, conference abstracts, and clinical trials, with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference databases.

The company was founded in 2023 in Montreal and Berlin by Karl Moritz Hermann (former DeepMind senior staff researcher), Marc G. Bellemare (former Google Brain/DeepMind, Canada CIFAR AI Chair at Mila), and Richard Schlegel (former EY-Parthenon Life Sciences Strategy). It raised $11.3M in seed funding in August 2024, co-led by Tola Capital and Inovia Capital, with additional participation from Mike Volpi, Amit Agarwal, and Yoshua Bengio; total disclosed funding reached $13.5M. By the time of acquisition the team was approximately 30 people operating across Montreal, Berlin, Boston, Denver, and London.

Reliant AI monetized through enterprise SaaS subscriptions for Reliant Tabular, milestone-based professional services, and Integration Partnership engagements with named customers including GSK, Kyowa Kirin, Ipsen, OMass Therapeutics, Medicus Pharma, and life sciences consulting firms such as Hayden Consulting Group. On May 19, 2026, Reliant AI was acquired by Cohere Inc., and the company, its biomedical datasets, and its workbench were integrated into Cohere's "North for Pharma" agentic AI platform; co-founders Hermann and Bellemare became vice presidents at Cohere.

Short descriptiontext

Reliant AI built Reliant Tabular, an AI workbench that automates systematic literature reviews, competitive landscaping, and clinical trial analytics for biopharma companies and life sciences consultancies. The Montreal-based company was acquired by Cohere in May 2026.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharma data analytics, life sciences AI, systematic literature reviews, competitive intelligence software, clinical trial analytics
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Biopharma AI Analytics Software
No data
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model4 records
1Enterprise SaaS subscriptions for Reliant Tabular
TypeSubscription Recurring
Description

Recurring subscriptions to the Reliant Tabular workbench with flexible and scalable pricing tailored to team needs, including unlimited extractions, abstracts, and systematic literature reviews across all plans.

reliant.ai
2Enterprise custom deployment and integration partnerships
TypeProfessional Services
Description

Custom enterprise deployment engagements that include bespoke data pipeline integration, use-case specific benchmarking, and feature prioritization; offered via internal deployment or API access as Integration Partnerships.

reliant.ai
3Milestone-based professional services engagements
TypeProfessional Services
Description

One-year milestone-based services agreements for tailored use cases (e.g., Medicus Pharma engagement capped at $200,000 for an AI-driven clinical data analytics platform supporting trial execution).

thepublicopinion.com
4White paper, blog and trend-report content marketing to drive inbound pipeline
TypeSubscription Recurring
Description

Free published research, white papers, blogs, and a paid 2026 Life Sciences AI Trend Report used as a top-of-funnel demand generation and lead capture mechanism.

reliant.ai
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details3 tiers
1Flexible, scalable enterprise pricing - quote-based
ModelOtherBilling cadenceAnnual
Notes

Pricing is not publicly listed; free trial available; all plans include unlimited full-text files, unlimited abstracts, unlimited systematic literature reviews, and conference database access.

reliant.ai
2Milestone-based services engagement (one-year, capped at $200,000)
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

One-year, milestone-based services agreement valued up to $200,000 over 12 months for the initial phase of the Medicus Pharma collaboration.

thepublicopinion.com
3Free trial / Self-serve sign-in to Reliant Tabular
ModelFreemiumBilling cadencePay-as-you-go
Notes

Self-serve Sign In to the Tabular workbench at tabular.reliant.ai and a 'Get free trial' CTA are available, with upgrade paths to enterprise plans.

reliant.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Reliant Tabular
Description

AI workbench for biopharma analysts designed to automate systematic literature reviews, evidence-based decision-making, competitive landscaping, and data extraction for pharmaceutical and biotechnology industries.

reliant.ai
Core offering1 text field

Reliant AI provides Reliant Tabular, a generative-AI-powered data analytics workbench purpose-built for the biopharma industry. The platform automates systematic literature reviews, competitive landscaping, asset benchmarking, clinical trial site selection, and structured scientific data extraction by combining proprietary fine-tuned large language models with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. The platform is delivered as enterprise SaaS with an enterprise tier offering custom data pipelines, data lake integration, and API/internal deployment for bespoke life sciences workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 200x faster than manual methods for systematic literature reviews (oncology case study)
+9 more records
Product overview1 text field

Reliant AI offers a single integrated AI product platform anchored by Reliant Tabular, an applied-AI workbench purpose-built for the life sciences industry. Reliant Tabular is the core platform that combines proprietary generative AI and machine learning pipelines (including fine-tuned large language models) with native data integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. On top of this core platform, Reliant AI delivers two primary use-case modules: an Evidence Synthesis / Literature Reviews module for systematic, targeted, and rapid literature reviews with risk of bias assessment, and a Competitive Landscaping module for forecasting, asset benchmarking, and competitive intelligence. These modules are complemented by an Enterprise Offering & Integration Partnerships tier that provides custom data pipelines, data lake integration, and API access for bespoke deployments. Reliant AI also publishes research, including its 2026 Life Sciences AI Trend Report. Following Cohere's May 2026 acquisition, Reliant Tabular's technology and team have been folded into Cohere's "North for Pharma" agentic AI system for biopharma workflows.

Product and service2 records
1Reliant Tabular
CategoryAI analytics platform for life sciences
Description

Reliant Tabular is Reliant AI's flagship generative-AI-powered data analytics workbench for the biopharma industry. It automates systematic literature reviews, competitive landscaping, asset benchmarking, and structured scientific data extraction for life sciences teams, with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. Sold to enterprise and mid-market biopharma, biotech, and life sciences consulting teams.

2Enterprise Offering & Integration Partnerships
CategoryEnterprise deployment and integration services
Description

Enterprise tier of Reliant Tabular offering custom data pipelines for data lake integration, adaptation to enterprise IT security and audit requirements, and bespoke use-case workflows and templates. The Integration Partnerships tier adds internal deployment or API access with feature prioritization and custom data integration configurations. Sold to large pharmaceutical and biotech enterprises.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierAcquirer / Parent CompanyTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Acquired Reliant AI on May 19, 2026 to expand into biopharma and healthcare. Reliant AI's research team, proprietary biomedical datasets, and Reliant Tabular workbench are being integrated into Cohere's enterprise AI platform as 'North for Pharma'; co-founders Karl Moritz Hermann and Marc Bellemare became Cohere VPs.

Strategic tierStrategic Pilot PartnerTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Non-binding letter of intent to jointly develop an AI-powered clinical data analytics platform for trial execution. Initial one-year, milestone-based services engagement capped at $200,000 focused on dynamic site selection and patient stratification for a Teverelix clinical study planned for 2026, with potential expansion to a larger late-stage study in 2028.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Elicit is an AI research assistant that automates literature review and evidence synthesis for scientists. Reliant AI's website explicitly publishes a competitor-comparison page against Elicit, positioning Tabular as the domain-specialized alternative for biopharma systematic literature reviews.

TypeDirect peer
Description

Causaly is an AI platform for biomedical research that builds knowledge graphs over scientific literature to support drug discovery and competitive intelligence. It overlaps directly with Reliant Tabular's densified knowledge graphs and competitive-landscaping workflows for pharma.

TypeDirect peer
Description

Iris.ai provides an AI engine for scientific text analysis and R&D knowledge management. Like Reliant, it targets enterprise R&D teams with tools for literature review, patent analysis, and structured data extraction across scientific publications.

TypeBroad incumbent
Description

Owkin is an AI biotech company applying machine learning to clinical research and drug development for major pharma partners. It sits in the same biopharma-AI category as Reliant but operates a broader federated-learning and trial-optimization platform rather than a literature workbench.

TypeBroad incumbent
Description

Insilico Medicine is an AI-driven drug discovery company combining generative chemistry, biology, and clinical trial analytics. It competes with Reliant in pharma AI workflows but spans the full discovery-to-clinic value chain rather than focusing on evidence synthesis.

TypeBroad incumbent
Description

BenevolentAI applies knowledge graphs and machine learning to drug discovery and development for pharma. It overlaps with Reliant's biomedical knowledge-graph approach but is positioned further upstream in target identification and pipeline prioritization.

TypeBroad incumbent
Description

IQVIA is the world's largest life-sciences analytics and clinical research services provider, with AI-augmented offerings spanning evidence synthesis, competitive intelligence, and clinical trial design. Reliant targets IQVIA-style use cases with a more focused, AI-native workbench.

TypeDirect peer
Description

Scite uses AI to classify and contextualize scientific citations, helping researchers evaluate evidence. Like Reliant, it sits in the AI-for-literature-review category used by biopharma analysts and competes for the same end-user workflow.

9Tempus Labs
TypeBroad incumbent
Description

Tempus is an AI-powered precision medicine company combining clinical and molecular data for pharma and providers. It competes with Reliant in pharma-facing AI analytics (especially trial site selection and patient stratification) but at much greater scale.

TypeBroad incumbent
Description

Veeva is the dominant cloud-software platform for the global life-sciences industry, spanning commercial, clinical, regulatory, and data workflows. Several Reliant employees came from Veeva, and Veeva's data-and-AI portfolio overlaps with Reliant's competitive-landscaping and trial use cases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Reliant AI

Biopharma AI Analytics Softwarereliant.ai

Reliant AI built Reliant Tabular, an AI workbench that automates systematic literature reviews, competitive landscaping, and clinical trial analytics for biopharma companies and life sciences consultancies. The Montreal-based company was acquired by Cohere in May 2026.

What Reliant AI does

Reliant AI was a Canadian applied-AI company that built domain-specific generative AI tooling for the biopharma industry. Its flagship product, Reliant Tabular, was an AI workbench that automated systematic literature reviews, competitive landscaping, evidence synthesis, and clinical trial analytics for pharmaceutical and biotechnology companies and the consulting firms that serve them. The platform combined proprietary fine-tuned large language models (including a fine-tuned version of Llama 3.1 70B), reinforcement learning, retrieval-augmented generation, and "densified knowledge graphs" covering 38M+ scientific publications, conference abstracts, and clinical trials, with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference databases.

The company was founded in 2023 in Montreal and Berlin by Karl Moritz Hermann (former DeepMind senior staff researcher), Marc G. Bellemare (former Google Brain/DeepMind, Canada CIFAR AI Chair at Mila), and Richard Schlegel (former EY-Parthenon Life Sciences Strategy). It raised $11.3M in seed funding in August 2024, co-led by Tola Capital and Inovia Capital, with additional participation from Mike Volpi, Amit Agarwal, and Yoshua Bengio; total disclosed funding reached $13.5M. By the time of acquisition the team was approximately 30 people operating across Montreal, Berlin, Boston, Denver, and London.

Reliant AI monetized through enterprise SaaS subscriptions for Reliant Tabular, milestone-based professional services, and Integration Partnership engagements with named customers including GSK, Kyowa Kirin, Ipsen, OMass Therapeutics, Medicus Pharma, and life sciences consulting firms such as Hayden Consulting Group. On May 19, 2026, Reliant AI was acquired by Cohere Inc., and the company, its biomedical datasets, and its workbench were integrated into Cohere's "North for Pharma" agentic AI platform; co-founders Hermann and Bellemare became vice presidents at Cohere.

Reliant AI firmographics

Firmographics
Name
Reliant AI
Legal name
Reliant AI, Inc.
Website
https://reliant.ai
Company type
Private
Founded year
2023
Operating status
Acquired
Headcount range
1–10 employees
Short description
Reliant AI built Reliant Tabular, an AI workbench that automates systematic literature reviews, competitive landscaping, and clinical trial analytics for biopharma companies and life sciences consultancies. The Montreal-based company was acquired by Cohere in May 2026.
Ownership category
akta.pro rank

Reliant AI industry classification

Industry
Product category
Biopharma AI Analytics Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Biopharma data analytics
  • Life sciences AI
  • Systematic literature reviews
  • Competitive intelligence software
  • Clinical trial analytics

Where Reliant AI is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices5 records

Markets served

Reliant AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise SaaS subscriptions for Reliant Tabular: Recurring subscriptions to the Reliant Tabular workbench with flexible and scalable pricing tailored to team needs, including unlimited extractions, abstracts, and systematic literature reviews across all plans.
  2. Enterprise custom deployment and integration partnerships: Custom enterprise deployment engagements that include bespoke data pipeline integration, use-case specific benchmarking, and feature prioritization; offered via internal deployment or API access as Integration Partnerships.
  3. Milestone-based professional services engagements: One-year milestone-based services agreements for tailored use cases (e.g., Medicus Pharma engagement capped at $200,000 for an AI-driven clinical data analytics platform supporting trial execution).
  4. White paper, blog and trend-report content marketing to drive inbound pipeline: Free published research, white papers, blogs, and a paid 2026 Life Sciences AI Trend Report used as a top-of-funnel demand generation and lead capture mechanism.

Pricing tiers

ModelBillingPrice
OtherAnnualFlexible, scalable enterprise pricing - quote-based
Outcome Based/ PerformanceMulti-year contractMilestone-based services engagement (one-year, capped at $200,000)
FreemiumPay-as-you-goFree trial / Self-serve sign-in to Reliant Tabular

Go-to-market motion5 records

Distribution channels4 records

Marketing channels10 records

Reliant AI product offering

Product offering

Core offering

Reliant AI provides Reliant Tabular, a generative-AI-powered data analytics workbench purpose-built for the biopharma industry. The platform automates systematic literature reviews, competitive landscaping, asset benchmarking, clinical trial site selection, and structured scientific data extraction by combining proprietary fine-tuned large language models with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. The platform is delivered as enterprise SaaS with an enterprise tier offering custom data pipelines, data lake integration, and API/internal deployment for bespoke life sciences workflows.

Product overview

Reliant AI offers a single integrated AI product platform anchored by Reliant Tabular, an applied-AI workbench purpose-built for the life sciences industry. Reliant Tabular is the core platform that combines proprietary generative AI and machine learning pipelines (including fine-tuned large language models) with native data integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. On top of this core platform, Reliant AI delivers two primary use-case modules: an Evidence Synthesis / Literature Reviews module for systematic, targeted, and rapid literature reviews with risk of bias assessment, and a Competitive Landscaping module for forecasting, asset benchmarking, and competitive intelligence. These modules are complemented by an Enterprise Offering & Integration Partnerships tier that provides custom data pipelines, data lake integration, and API access for bespoke deployments. Reliant AI also publishes research, including its 2026 Life Sciences AI Trend Report. Following Cohere's May 2026 acquisition, Reliant Tabular's technology and team have been folded into Cohere's "North for Pharma" agentic AI system for biopharma workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • Reliant Tabular: AI workbench for biopharma analysts designed to automate systematic literature reviews, evidence-based decision-making, competitive landscaping, and data extraction for pharmaceutical and biotechnology industries.

Products and services

  • Reliant Tabular Reliant Tabular is Reliant AI's flagship generative-AI-powered data analytics workbench for the biopharma industry. It automates systematic literature reviews, competitive landscaping, asset benchmarking, and structured scientific data extraction for life sciences teams, with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. Sold to enterprise and mid-market biopharma, biotech, and life sciences consulting teams.
  • Enterprise Offering & Integration Partnerships Enterprise tier of Reliant Tabular offering custom data pipelines for data lake integration, adaptation to enterprise IT security and audit requirements, and bespoke use-case workflows and templates. The Integration Partnerships tier adds internal deployment or API access with feature prioritization and custom data integration configurations. Sold to large pharmaceutical and biotech enterprises.

Quantifiable outcome

  • 200x faster than manual methods for systematic literature reviews (oncology case study)
  • +9 more outcomes

Companies that use Reliant AI

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Reliant AI technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability10 records

Feature7 records

Reliant AI partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered acquirer / parent company and strategic pilot partner.

  • Cohereacquirer / parent companyStrategic or Co-development Partner · 19 May 2026Acquired Reliant AI on May 19, 2026 to expand into biopharma and healthcare. Reliant AI's research team, proprietary biomedical datasets, and Reliant Tabular workbench are being integrated into Cohere's enterprise AI platform as 'North for Pharma'; co-founders Karl Moritz Hermann and Marc Bellemare became Cohere VPs.
  • Medicus Pharmastrategic pilot partnerStrategic or Co-development Partner · 22 December 2025Non-binding letter of intent to jointly develop an AI-powered clinical data analytics platform for trial execution. Initial one-year, milestone-based services engagement capped at $200,000 focused on dynamic site selection and patient stratification for a Teverelix clinical study planned for 2026, with potential expansion to a larger late-stage study in 2028.

Scale indicators16 records

Recent moves6 records

Expansion highlights7 records

Reliant AI competitors and assessment

Company assessment

Direct peers

  • Elicit: Elicit is an AI research assistant that automates literature review and evidence synthesis for scientists. Reliant AI's website explicitly publishes a competitor-comparison page against Elicit, positioning Tabular as the domain-specialized alternative for biopharma systematic literature reviews.
  • Causaly: Causaly is an AI platform for biomedical research that builds knowledge graphs over scientific literature to support drug discovery and competitive intelligence. It overlaps directly with Reliant Tabular's densified knowledge graphs and competitive-landscaping workflows for pharma.
  • Iris.ai: Iris.ai provides an AI engine for scientific text analysis and R&D knowledge management. Like Reliant, it targets enterprise R&D teams with tools for literature review, patent analysis, and structured data extraction across scientific publications.
  • Scite (scite.ai): Scite uses AI to classify and contextualize scientific citations, helping researchers evaluate evidence. Like Reliant, it sits in the AI-for-literature-review category used by biopharma analysts and competes for the same end-user workflow.

Broad incumbents

  • Owkin: Owkin is an AI biotech company applying machine learning to clinical research and drug development for major pharma partners. It sits in the same biopharma-AI category as Reliant but operates a broader federated-learning and trial-optimization platform rather than a literature workbench.
  • Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company combining generative chemistry, biology, and clinical trial analytics. It competes with Reliant in pharma AI workflows but spans the full discovery-to-clinic value chain rather than focusing on evidence synthesis.
  • BenevolentAI: BenevolentAI applies knowledge graphs and machine learning to drug discovery and development for pharma. It overlaps with Reliant's biomedical knowledge-graph approach but is positioned further upstream in target identification and pipeline prioritization.
  • IQVIA: IQVIA is the world's largest life-sciences analytics and clinical research services provider, with AI-augmented offerings spanning evidence synthesis, competitive intelligence, and clinical trial design. Reliant targets IQVIA-style use cases with a more focused, AI-native workbench.
  • Tempus Labs: Tempus is an AI-powered precision medicine company combining clinical and molecular data for pharma and providers. It competes with Reliant in pharma-facing AI analytics (especially trial site selection and patient stratification) but at much greater scale.
  • Veeva Systems: Veeva is the dominant cloud-software platform for the global life-sciences industry, spanning commercial, clinical, regulatory, and data workflows. Several Reliant employees came from Veeva, and Veeva's data-and-AI portfolio overlaps with Reliant's competitive-landscaping and trial use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Reliant AI compliance and trust

Trust signal

Compliance2 records

Reliant AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Reliant AI leadership team

Management profile

Number of profiles

Profiles9 records

Reliant AI funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Reliant AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reliant AI

What does Reliant AI do?

Reliant AI provides Reliant Tabular, a generative-AI-powered data analytics workbench purpose-built for the biopharma industry. The platform automates systematic literature reviews, competitive landscaping, asset benchmarking, clinical trial site selection, and structured scientific data extraction by combining proprietary fine-tuned large language models with native integrations to PubMed, Medline, Clinicaltrials.gov, FDA labels, and conference abstracts. The platform is delivered as enterprise SaaS with an enterprise tier offering custom data pipelines, data lake integration, and API/internal deployment for bespoke life sciences workflows.

Is Reliant AI a public or private company?

Reliant AI is a private company. It is classified as corporate owned and is currently acquired.

When was Reliant AI founded?

Reliant AI was founded in 2023. It employs 1 to 10 people.

Where is Reliant AI based?

Reliant AI is headquartered in Montreal, Canada, in the North America region.

How does Reliant AI make money?

Four revenue lines are on record. Enterprise SaaS subscriptions for Reliant Tabular is the primary driver. The others are enterprise custom deployment and integration partnerships, milestone-based professional services engagements and white paper, blog and trend-report content marketing to drive inbound pipeline.

Who are Reliant AI's main competitors?

Direct peers on record are Elicit, Causaly, Iris.ai and Scite (scite.ai). Broad incumbents are Owkin, Insilico Medicine, BenevolentAI, IQVIA, Tempus Labs and Veeva Systems.

Does Reliant AI have an API?

Yes. Enterprise and integration partners can access Reliant Tabular via API as part of bespoke integration configurations. Offered through the "Integration Partnerships" tier, which includes internal deployment or API access, feature prioritization, use-case specific benchmarking, and bespoke data integration configurations. Availability is limited to partners and enterprise customers (not a public developer API). Developer documentation is at www.reliant.ai/contact.

What industry is Reliant AI in?

Reliant AI's product category is Biopharma AI Analytics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Healthcare Technology Report.Cohere Acquires Reliant AI to Launch Sovereign Biopharma PlatformEnterprise AI provider Cohere has acquired Reliant AI, a Montreal- and Berlin-based specialist in biopharma data analytics, integrating the company's research team, specialized biomedical datasets, and domain-optimized technology into Cohere's enterprise platform. As part of the transaction, Cohere assumes Reliant AI's existing customer relationships and will use the acquired capabilities to develop "North for Pharma," an agentic AI system designed to automate workflows within the regulated life sciences sector. The acquisition expands Cohere's portfolio of jurisdiction-specific sovereign AI offerings in Canada and Germany, where data privacy regulations are strictly enforced, with Reliant AI's co-founders joining Cohere's vertical operations leadership.IntuitionLabsCohere Reliant AI Acquisition: North for Pharma ExplainedOn May 19, 2026, Cohere Inc., a Toronto-based enterprise AI startup, announced the acquisition of Reliant AI, a Montreal- and Berlin-based biopharma AI firm, in an all-stock deal (terms undisclosed) that closed immediately. Cohere will integrate Reliant's team, proprietary biomedical datasets, and domain-optimized AI technology into its North platform as a new vertical called "North for Pharma" — an agentic AI system for drug R&D, clinical development, and scientific analytics. Through the acquisition, Cohere inherits Reliant's existing pharmaceutical customers including GSK and Kyowa Kirin, strengthening Cohere's position in the competitive market for AI-powered biomedical research workbenches.Pulse 2.0Cohere Acquires Reliant AI To Expand Into Biopharma And HealthcareCohere announced the acquisition of Reliant AI, bringing the startup's research team, proprietary biomedical datasets, and intelligent research workbench platform into Cohere's enterprise AI portfolio to expand into biopharma and healthcare. Reliant AI's technology automates systematic literature reviews, competitive intelligence gathering, and scientific data extraction for pharmaceutical companies. The acquisition supports the expansion of North for Pharma, Cohere's agentic AI system for biopharma workflows, and expands Cohere's customer relationships with major pharmaceutical companies including GSK and Kyowa Kirin.AI Business InformsFlurry of Deals Reaffirms Sizzling AI MarketSeveral major AI companies announced acquisitions within a 24-hour period, including Anthropic buying Stainless, Mistral acquiring Emmi AI, and Cohere acquiring Reliant AI. These acquisitions aim to strengthen their respective AI development, industrial, and biopharma offerings.HpcwireCovering Scientific & Technical AICohere announced the acquisition of Reliant AI on May 19, 2026, bringing the biopharma AI company’s research team, proprietary biomedical datasets, and domain-optimized technology into Cohere’s enterprise sovereign AI platform. The deal expands Cohere’s footprint in global healthcare and life sciences and includes assumption of Reliant AI’s customer relationships with major pharmaceutical companies including GSK, Medicus Pharma, and Kyowa Kirin. The combined entity will accelerate development of North for Pharma, an agentic AI system for the biopharma sector, with Reliant AI’s co-founders joining Cohere in leadership roles.HpcwireData Science • AI • Advanced AnalyticsCohere announced the acquisition of Reliant AI, a biopharma AI company with operations in Montreal and Berlin, to expand its healthcare and life sciences offerings. The acquisition enhances Cohere's sovereignty and security features, focusing on highly regulated environments. Reliant AI's platform improves decision-making and research efficiency in the biopharma sector, with key customer relationships being assumed by Cohere.ThelogicCohere buys Montreal’s Reliant AI in pharma market pushCohere has acquired Montreal-based Reliant AI, a pharmaceutical AI startup founded by former Google DeepMind researchers Karl Moritz Hermann and Marc Bellemare, to expand its North AI platform into the pharma sector. The deal brings Reliant's team of researchers, specialized algorithms for drug discovery, and existing clients including GSK, Ipsen, and Kyowa Kirin, as Cohere continues its expansion into regulated industries and pursues a planned merger with German AI firm Aleph Alpha. Cohere is simultaneously raising a new funding round in which Schwarz Group has committed US$600 million.Let's Data ScienceCohere Acquires Reliant AI for Biopharma AnalyticsCohere has acquired Reliant AI, a biopharma analytics firm based in Montreal and Berlin. The acquisition includes Reliant's research team, proprietary biomedical datasets, and an intelligent research workbench, which will be integrated into Cohere's platform as North for Pharma.BetaKitCohere acquires second company with German ties in Reliant AIToronto-based AI company Cohere has acquired Reliant AI, a Montréal- and Berlin-based biopharmaceutical data processing startup, marking Cohere's second acquisition in a month as it seeks to expand into the healthcare sector with its North for Pharma enterprise AI platform. The deal brings Reliant AI's research team of over 30 employees, proprietary biomedical datasets, and domain-optimized technology into Cohere's portfolio, along with customer relationships including pharmaceutical giants GSK, Ipsen, and Kyowa Kirin. Cohere CEO Aidan Gomez stated that healthcare represents one of the most consequential opportunities for AI, positioning the acquisition as part of the company's strategy to offer sovereign AI solutions focused on security, data privacy, and regulatory compliance.The Globe and MailCohere acquires Reliant AI, expanding presence in life sciencesCohere Inc. is acquiring Reliant AI, a biopharma-focused AI company with operations in Montreal and Berlin, to expand its presence in the life sciences sector. The acquisition follows Cohere's previous merger with German AI company Aleph Alpha, aiming to enhance industry-specific AI tools.